Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

RETA | Reata Pharmaceuticals, Inc.

Index	RUT	P/E	-	EPS (ttm)	-2.99	Insider Own	4.10%	Shs Outstand	37.67M	Perf Week	0.19%
Market Cap	6.57B	Forward P/E	-	EPS next Y	-4.40	Insider Trans	-14.46%	Shs Float	27.58M	Perf Month	1.87%
Income	-87.60M	PEG	-	EPS next Q	-2.09	Inst Own	89.30%	Short Float / Ratio	9.41% / 2.71	Perf Quarter	83.73%
Sales	23.50M	P/S	279.45	EPS this Y	-4.30%	Inst Trans	-0.00%	Short Interest	2.60M	Perf Half Y	95.93%
Book/sh	2.32	P/B	74.28	EPS next Y	34.10%	ROA	-17.10%	Target Price	172.45	Perf Year	597.09%
Cash/sh	8.66	P/C	19.89	EPS next 5Y	-	ROE	335.20%	52W Range	21.83 - 172.36	Perf YTD	353.59%
Dividend	-	P/FCF	-	EPS past 5Y	-33.80%	ROI	420.00%	52W High	-0.02%	Beta	1.41
Dividend %	-	Quick Ratio	3.20	Sales past 5Y	-46.00%	Gross Margin	96.40%	52W Low	689.37%	ATR	0.99
Employees	321	Current Ratio	3.20	Sales Q/Q	2885.00%	Oper. Margin	-	RSI (14)	84.61	Volatility	0.11% 0.31%
Optionable	Yes	Debt/Eq	0.84	EPS Q/Q	330.50%	Profit Margin	-	Rel Volume	0.78	Prev Close	172.17
Shortable	Yes	LT Debt/Eq	0.84	Earnings	-	Payout	-	Avg Volume	958.30K	Price	172.32
Recom	3.00	SMA20	1.07%	SMA50	10.48%	SMA200	83.90%	Volume	748,867	Change	0.09%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-06-23	Initiated	TD Cowen	Outperform	$140
Jun-12-23	Upgrade	SVB Securities	Market Perform → Outperform	$80 → $115
Oct-19-22	Initiated	Guggenheim	Buy	$75
Mar-24-22	Resumed	Goldman	Buy	$91
Dec-09-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$35
Dec-09-21	Downgrade	Robert W. Baird	Outperform → Neutral	$110 → $37
May-24-21	Initiated	Goldman	Buy	$236
Apr-26-21	Initiated	Barclays	Overweight	$155
Jul-10-20	Resumed	Stifel	Buy	$315 → $280
Jun-17-20	Initiated	BTIG Research	Buy	$237
Nov-13-19	Downgrade	National Securities	Buy → Neutral
Sep-26-19	Initiated	National Securities	Buy	$130
Sep-25-18	Reiterated	Leerink Partners	Outperform	$116 → $139
Sep-13-17	Initiated	Leerink Partners	Outperform	$43
Jul-25-17	Reiterated	Citigroup	Buy	$39 → $87
Apr-13-17	Initiated	Ladenburg Thalmann	Buy	$55
Feb-23-17	Initiated	Stifel	Buy	$38
Jan-25-17	Initiated	Robert W. Baird	Outperform	$43
Jun-20-16	Initiated	Piper Jaffray	Overweight	$33
Jun-20-16	Initiated	Citigroup	Buy

Show Previous Ratings

Sep-21-23 10:08AM	Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc. (Business Wire)
Sep-09-23 07:45AM	Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy? (Motley Fool)
Sep-08-23 05:06PM	Insider Sell: SVP, Chief Accounting Officer Bhaskar Anand Sells 406 Shares of Reata ... (GuruFocus.com)
Sep-07-23 06:30AM	The Petri Dish: Biogen secures $1.5B loan; Mersana CEO departs after trial failure (American City Business Journals)
Sep-01-23 02:00PM	Top Growth Stocks for September 2023 (Investopedia)
11:30AM	Loading…
11:30AM	Top Stocks for September 2023 (Investopedia)
Aug-31-23 08:30AM	The 7 Most Promising Momentum Stocks to Own Now (InvestorPlace)
Aug-30-23 05:20AM	The 3 Most Promising Pharma Stocks to Own Now (InvestorPlace)
Aug-22-23 08:00AM	These Are The 5 Best Stocks Of The Year; Some You May Not Recognize (Investor's Business Daily)
Aug-16-23 03:12PM	15 Best Performing Stocks in the Last 3 Months (Insider Monkey)
Aug-10-23 09:00AM	Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around? (Motley Fool)
Aug-09-23 08:30AM	With an Acquisition on the Way, Is Biogen Stock a Buy? (Motley Fool)
Aug-01-23 11:03PM	CPMG Inc Acquires Significant Stake in Reata Pharmaceuticals Inc (GuruFocus.com)
05:45AM	Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know. (Motley Fool)
Jul-31-23 06:13AM	Could This Stock Be the Next Biotech Buyout? (Motley Fool)
02:12AM	Loading…
02:12AM	4 big deal reports: Biogen shells out $7.3B for Reata Pharma (Investing.com)
Jul-28-23 04:24PM	Biogen Buys Reata Pharmaceuticals, Expanding Its Lineup of Rare Disease Drugs (Investopedia) +54.02%
04:07PM	Biogen Announces $7.3 Billion Acquisition After Outlining Plans To Cut 11% Of Workforce (Investor's Business Daily)
04:07PM	Biogen to buy rare-disease drugmaker Reata in $7.3B deal (Yahoo Finance Video)
02:21PM	Why Biogen Agreed to Acquire Reata for $7.3 Billion (Bloomberg)
12:41PM	Biogen Buying Rare-Disease Drugmaker in $7.3 Billion Deal (The Wall Street Journal)
10:53AM	Enphase Energy outlook, Biogen-Reata deal, Boston Beer stock: Top stocks (Yahoo Finance Video)
10:39AM	Reata Stock Surges. Biogen Is Buying It for $7.3 Billion in Cash. (Barrons.com)
10:35AM	Biogen to Buy Reata for $7.3 Billion in Rare-Disease Deal (Bloomberg)
08:43AM	Will Biogen's Deal Splash Give Biotech a Lift? (The Wall Street Journal)
08:03AM	Biogen to Buy Reata Pharmaceuticals in $7.3 Billion Deal (The Wall Street Journal)
07:57AM	Biogen to bulk up rare disease treatments with $7 billion Reata acquisition (AP Finance)
07:21AM	Biogen to buy Reata for $6.5 billion to bulk up rare disease portfolio (Reuters)
07:09AM	UPDATE 4-Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio (Reuters)
07:05AM	Biogen to Acquire Reata Pharmaceuticals (GlobeNewswire)
07:01AM	Loading…
07:01AM	Biogen considering takeover of biotech Reata - Bloomberg Law (Reuters)
Jul-23-23 05:24AM	TipRanks Perfect 10 List: Analysts Pound the Table on These Top-Rated Stocks (TipRanks)
Jul-21-23 11:19AM	12 Under-the-Radar Stocks That Are on The Move (Insider Monkey)
Jul-13-23 07:45AM	3 Top Biotech Stocks Defying the Bear Market (Motley Fool)
Jul-06-23 11:22AM	15 Best NASDAQ Stocks To Buy Today (Insider Monkey)
Jun-29-23 04:10PM	Reata Surges 12% Over Three Days; CEO Reflects On The Tricky Path To Launch A First-Ever Drug (Investor's Business Daily)
01:11PM	Reata Surges 16% Over Three Days; CEO Reflects On The Tricky Path To Launch A First-Ever Drug (Investor's Business Daily)
09:18AM	Reata's (RETA) Skyclarys PAS Gets FDA Nod, Stock Rises 7% (Zacks)
06:20AM	Reata Pharmaceuticals, Inc. (RETA) Moves 7.0% Higher: Will This Strength Last? (Zacks)
Jun-28-23 04:11PM	Reata Nears Breakout After Snagging FDA Blessing To Launch Its Friedreich's Ataxia Drug (Investor's Business Daily) +6.97%
Jun-27-23 07:29PM	Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreichs Ataxia (Business Wire)
Jun-19-23 10:28AM	Reata (RETA) Announces FDA's Acceptance of Skyclarys PAS (Zacks)
Jun-16-23 04:02PM	Top 1% Biotech Stock Reata Pharmaceuticals Faces Another Hurdle (Investor's Business Daily)
Jun-15-23 07:15PM	Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement (Business Wire) -8.42%
06:38AM	Daily Vickers Top Buyers & Sellers for 06/15/2023 (Argus Research)
Jun-13-23 03:10PM	10 Under-the-Radar Stocks Billionaires Are Loading Up On (Insider Monkey) +5.24%
06:45AM	Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer (Business Wire)
Jun-09-23 11:30AM	Why Is Reata Pharmaceuticals, Inc. (RETA) Up 6.9% Since Last Earnings Report? (Zacks)
Jun-07-23 06:38AM	Investors ignore increasing losses at Reata Pharmaceuticals (NASDAQ:RETA) as stock jumps 4.7% this past week (Simply Wall St.)
Jun-06-23 04:31PM	Reata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference (Business Wire)
May-24-23 12:48PM	PTC Therapeutics' (PTCT) Rare Disease Drug Fails in Study (Zacks) +20.37%
May-18-23 01:50PM	Top Pharmaceutical Stocks for Q2 2023 (Investopedia)
06:39AM	Daily Vickers Top Buyers & Sellers for 05/18/2023 (Argus Research)
May-11-23 09:44AM	Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates (Zacks)
06:00AM	Reata Pharmaceuticals First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-10-23 04:04PM	Top 1% Biotech Reata Crashes On A Delay For Its Most Anticipated Drug (Investor's Business Daily) -14.23%
09:21AM	Reata Pharma Tumbles After Scrapping Its Kidney Drug As Earnings Come In Mixed (Investor's Business Daily)
06:40AM	Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results and Provides an Update on Operational Progress and Clinical Development Programs (Business Wire)
May-02-23 05:45PM	Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023 (Business Wire)
10:01AM	Analysts Estimate Janux Therapeutics, Inc. (JANX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-28-23 11:31AM	Q1 2023 PTC Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-12-23 12:07PM	Here's Why You Should Invest in Larimar (LRMR) Stock Now (Zacks)
Apr-11-23 05:39AM	3 Stocks That Already Doubled in 2023 and Could Keep Climbing (Motley Fool)
Mar-31-23 09:46AM	We're Hopeful That Reata Pharmaceuticals (NASDAQ:RETA) Will Use Its Cash Wisely (Simply Wall St.)
Mar-29-23 10:23PM	The 3 Best Growth Stocks to Buy in the Biotech Sector (InvestorPlace)
Mar-19-23 06:24AM	3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing (Motley Fool)
Mar-13-23 12:49PM	Reata (RETA) Stock Doubles This Year on Skyclarys FDA Nod (Zacks)
10:21AM	US Government Assures Fund Accessibility to SVB (SIVB) Clients (Zacks)
Mar-07-23 04:15PM	2 Top Healthcare Stocks Defying the Bear Market (Motley Fool)
Mar-06-23 07:22AM	Daily Vickers Top Buyers & Sellers for 03/06/2023 (Argus Research)
06:40AM	Reata Pharmaceuticals Announces Participation in the Barclays Global Healthcare Conference (Business Wire)
Mar-04-23 07:04AM	Reata Pharmaceuticals, Inc. (NASDAQ:RETA): Are Analysts Optimistic? (Simply Wall St.)
Mar-03-23 12:11PM	Biotech Stocks Fell on Fear of Less Flexible FDA. This Analyst Isnt Worried. (Barrons.com)
Mar-02-23 01:42PM	Why Reata Pharmaceuticals Stock Skyrocketed This Week (Motley Fool) -6.83%
06:43AM	Reata (RETA) Stock Jumps as FDA Approves Rare Disease Drug (Zacks)
Mar-01-23 04:10PM	Reata Pharma Stock Almost Triples After Winning 'Coin-Flip' FDA Approval (Investor's Business Daily) +198.91%
02:53PM	Reatas new rare-disease drug will cost $370,000 per year (MarketWatch)
02:30PM	Pharma Stock Surges After FDA Approves Treatment (Schaeffer's Investment Research)
12:49PM	FDA Widens Path for Rare-Disease Treatments With New Approval (The Wall Street Journal)
09:09AM	Investors Just Hit the Jackpot on These 2 Nasdaq Biotech Stocks (Motley Fool)
08:06AM	Reatas stock jumps 175% in premarket trading after FDA approval (MarketWatch)
07:17AM	Why Reata Pharma Shares Are Skyrocketing Today (Benzinga)
07:14AM	Reata Stock Soars on Approval for Rare Disorder Drug. Its Pipeline Impresses Analysts. (Barrons.com)
07:14AM	Reata Soars on Approval for Rare Disorder Drug. Its Pipeline Value Impresses Analysts. (Barrons.com)
04:53AM	FDAs approval of Friedreichs ataxia drug is a game changer for treatment of rare diseases (Quartz)
Feb-28-23 08:14PM	Reatas stock soars 150% after FDA approves rare-disease drug amid uncertainty about approach to neuroscience treatments (MarketWatch)
06:51PM	UPDATE 1-U.S. FDA approves Reata's rare genetic disorder drug (Reuters)
06:36PM	Reata Pharma Stock Skyrockets After Winning 'Coin-Flip' FDA Approval (Investor's Business Daily)
06:31PM	Reatas stock nearly triples after FDA approves rare-disease drug amid uncertainty about approach to neuroscience treatments (MarketWatch)
06:03PM	Reata Pharma Stock Halted After Winning 'Coin-Flip' FDA Approval (Investor's Business Daily)
05:39PM	FDA approves Reatas rare disease drug amid questions about changes to the regulatory environment for neuroscience treatments (MarketWatch)
05:25PM	Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreichs Ataxia (Business Wire)
01:41PM	FDA neurosciences chief Billy Dunn to leave immediately, analysts raise concern (Reuters)
Feb-27-23 04:06PM	Reata Stock Plummets As Official's Exit Shakes Up FDA's Neuroscience Unit (Investor's Business Daily) -30.69%
02:39PM	Why Reata Pharmaceuticals Shares Are Falling Monday? (Benzinga)
Feb-13-23 07:08AM	Provention Bio, Inc. (PRVB) Surges 11.5%: Is This an Indication of Further Gains? (Zacks)
Feb-03-23 04:36AM	Reata Pharmaceuticals, Inc. (RETA) Soars 6.3%: Is Further Upside Left in the Stock? (Zacks)
Feb-01-23 10:30AM	The Nasdaq Is Rebounding: 2 Supercharged Growth Stocks to Buy in February (Motley Fool) +7.43%
Dec-31-22 04:34PM	Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-28-22 12:32PM	15 Most Shorted Stocks Hedge Funds Are Buying (Insider Monkey)

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Loewen Andrea	SVP, Global Regulatory Affairs	Sep 14	Sale	172.03	3,175	546,181	28,416	Sep 18 05:34 PM
Anand Bhaskar	SVP, Chief Accounting Officer	Sep 05	Sale	169.20	406	68,695	24,089	Sep 07 04:11 PM
Soni Manmeet Singh	COO, CFO and President	Aug 16	Sale	168.41	1,755	295,566	62,621	Aug 17 04:43 PM
Meyer Colin John	Chief Innovation Officer	Aug 16	Sale	168.74	596	100,569	81,633	Aug 17 04:40 PM
WORTLEY MICHAEL D	Chief Legal Officer	Aug 16	Sale	168.76	398	67,167	49,701	Aug 17 04:46 PM
Bir Dawn Carter	Chief Commercial Officer	Aug 16	Sale	168.33	398	66,996	33,805	Aug 17 04:35 PM
Anand Bhaskar	SVP, Chief Accounting Officer	Aug 16	Sale	168.42	210	35,368	24,495	Aug 17 04:31 PM
Meyer Colin John	Chief Innovation Officer	Aug 15	Sale	169.07	2,144	362,483	82,229	Aug 17 04:40 PM
WORTLEY MICHAEL D	Chief Legal Officer	Aug 15	Sale	169.04	807	136,415	50,099	Aug 17 04:46 PM
Bir Dawn Carter	Chief Commercial Officer	Aug 15	Sale	169.04	807	136,413	34,203	Aug 17 04:35 PM
Anand Bhaskar	SVP, Chief Accounting Officer	Aug 15	Sale	169.06	193	32,628	24,705	Aug 17 04:31 PM
Ruff Shamim	Director	Jul 28	Option Exercise	92.20	8,235	759,267	15,594	Aug 01 04:41 PM
Soni Manmeet Singh	COO, CFO and President	Jul 28	Sale	164.62	75,000	12,346,298	64,376	Aug 01 04:47 PM
Bir Dawn Carter	Chief Commercial Officer	Jul 28	Sale	164.54	40,000	6,581,428	35,010	Aug 01 04:29 PM
Ruff Shamim	Director	Jul 28	Sale	164.53	8,235	1,354,887	7,359	Aug 01 04:41 PM
McClellan William D. Jr.	Director	Jul 28	Sale	164.49	5,000	822,442	6,017	Aug 01 04:35 PM
Anand Bhaskar	SVP, Chief Accounting Officer	Jun 14	Option Exercise	27.32	1,562	42,674	27,241	Jun 16 04:03 PM
Anand Bhaskar	SVP, Chief Accounting Officer	Jun 14	Sale	102.11	2,343	239,248	24,898	Jun 16 04:03 PM
Soni Manmeet Singh	COO, CFO and President	Jun 13	Option Exercise	27.32	25,000	683,000	136,461	Jun 14 04:35 PM
Soni Manmeet Singh	COO, CFO and President	Jun 13	Sale	102.89	78,085	8,034,343	58,376	Jun 14 04:35 PM
Soni Manmeet Singh	COO, CFO and President	Jun 12	Sale	99.62	4,711	469,297	111,461	Jun 14 04:35 PM
Meyer Colin John	Chief Innovation Officer	May 16	Sale	80.94	625	50,590	78,373	May 17 04:34 PM
Soni Manmeet Singh	COO, CFO and President	May 16	Sale	80.93	625	50,584	116,172	May 17 04:39 PM
WORTLEY MICHAEL D	Chief Legal Officer	May 16	Sale	80.99	417	33,773	46,781	May 17 04:51 PM
Bir Dawn Carter	Chief Commercial Officer	May 16	Sale	80.95	417	33,758	30,885	May 17 04:21 PM
Khan Samina	SVP, Chief Medical Officer	May 16	Sale	81.37	352	28,642	39,491	May 17 04:29 PM
Loewen Andrea	SVP, Global Regulatory Affairs	May 16	Sale	81.02	313	25,359	31,591	May 16 04:17 PM
Anand Bhaskar	SVP, Chief Accounting Officer	May 16	Sale	81.10	136	11,030	25,679	May 17 04:26 PM
Soni Manmeet Singh	COO, CFO and President	May 15	Sale	84.56	21,507	1,818,567	116,797	May 17 04:39 PM
Meyer Colin John	Chief Innovation Officer	May 15	Sale	84.96	5,608	476,473	78,998	May 17 04:34 PM
Anand Bhaskar	SVP, Chief Accounting Officer	May 15	Sale	85.98	950	81,684	25,815	May 17 04:26 PM
Bir Dawn Carter	Chief Commercial Officer	May 15	Sale	85.09	894	76,070	31,302	May 17 04:21 PM
WORTLEY MICHAEL D	Chief Legal Officer	May 15	Sale	84.81	894	75,816	47,198	May 17 04:51 PM
Khan Samina	SVP, Chief Medical Officer	May 15	Sale	85.32	288	24,572	39,843	May 17 04:29 PM
Loewen Andrea	SVP, Global Regulatory Affairs	May 15	Sale	84.71	103	8,725	31,904	May 16 04:17 PM
Loewen Andrea	SVP, Global Regulatory Affairs	May 12	Sale	86.26	6,750	582,267	32,007	May 16 04:17 PM
Bir Dawn Carter	Chief Commercial Officer	Mar 13	Sale	86.77	9,317	808,436	32,196	Mar 15 04:44 PM
Ruff Shamim	Director	Mar 10	Option Exercise	34.50	5,740	198,042	10,963	Mar 13 05:23 PM
Ruff Shamim	Director	Mar 10	Sale	83.73	5,740	480,610	5,223	Mar 13 05:23 PM
Loewen Andrea	SVP, Global Regulatory Affairs	Mar 07	Option Exercise	27.32	15,000	409,800	57,793	Mar 09 04:47 PM
Bir Dawn Carter	Chief Commercial Officer	Mar 07	Sale	85.20	42,042	3,582,002	41,513	Mar 08 05:17 PM
Loewen Andrea	SVP, Global Regulatory Affairs	Mar 07	Sale	83.43	19,036	1,588,137	38,757	Mar 09 04:47 PM
Khan Samina	SVP, Chief Medical Officer	Mar 07	Sale	83.46	3,961	330,585	40,131	Mar 08 04:56 PM
Soni Manmeet Singh	COO, CFO and President	Mar 07	Sale	84.69	622	52,680	88,304	Mar 08 05:01 PM
Meyer Colin John	Chief Innovation Officer	Mar 07	Sale	84.57	621	52,518	84,606	Mar 08 05:04 PM
WORTLEY MICHAEL D	Chief Legal Officer	Mar 07	Sale	84.46	414	34,966	48,092	Mar 08 04:59 PM
Anand Bhaskar	SVP, Chief Accounting Officer	Mar 07	Sale	84.58	165	13,956	26,765	Mar 08 05:08 PM
Bir Dawn Carter	Chief Commercial Officer	Mar 06	Sale	89.56	54,954	4,921,619	41,925	Mar 08 05:17 PM
Meyer Colin John	Chief Innovation Officer	Mar 03	Sale	87.35	5,286	461,732	85,227	Mar 06 05:04 PM
Soni Manmeet Singh	COO, CFO and President	Mar 03	Sale	87.97	3,587	315,548	88,926	Mar 06 04:48 PM
Khan Samina	SVP, Chief Medical Officer	Mar 03	Sale	87.36	2,813	245,744	44,092	Mar 06 04:40 PM
Bir Dawn Carter	Chief Commercial Officer	Mar 03	Sale	88.25	2,166	191,148	48,509	Mar 06 04:28 PM
WORTLEY MICHAEL D	Chief Legal Officer	Mar 03	Sale	87.57	2,169	189,939	48,506	Mar 06 04:51 PM
Loewen Andrea	SVP, Global Regulatory Affairs	Mar 03	Sale	87.73	1,601	140,456	42,793	Mar 06 04:44 PM
Anand Bhaskar	SVP, Chief Accounting Officer	Mar 03	Sale	87.47	820	71,725	26,930	Mar 06 04:31 PM
Khan Samina	SVP, Chief Medical Officer	Mar 02	Option Exercise	27.32	25,000	683,000	71,905	Mar 06 04:40 PM
Meyer Colin John	Chief Innovation Officer	Mar 02	Sale	86.69	88,636	7,683,492	90,513	Mar 06 05:04 PM
Huff James Warren	Chief Executive Officer	Mar 02	Sale	85.46	75,000	6,409,473	36,158	Mar 03 05:09 PM
Khan Samina	SVP, Chief Medical Officer	Mar 02	Sale	84.88	25,000	2,121,972	46,905	Mar 06 04:40 PM
Loewen Andrea	SVP, Global Regulatory Affairs	Mar 02	Sale	90.61	218	19,753	44,394	Mar 06 04:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RETA | Reata Pharmaceuticals, Inc.

Upgrade your FINVIZ experience